Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Fox Chase Cancer Center
With
National Comprehensive Cancer Network
This phase I trial will escalate doses of the histone deacetylase inhibitor (HDAC) vorinostat to a chemoradiation platform for cisplatin, pemetrexed and radiation to a dose of 70Gy in NSCLC patients with unresectable IIIA and dry IIIB disease. The endpoint will be to determine MTD of the combination.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
biopsy proven non-squamous NSCLC with unresectable stage IIIA or dry IIIB disease.
FEV1 \>/= 1 liter
ECOG PS 0 or 1
Able to swallow and absorb enterally
Measurable disease per RECIST 1.1
Adequate organ and marrow function including calculated creatinine clearance \>/= 60 mL/min hepatic enzymes and alk phos \</= 2.5 X ULN.
You may not be if
Chemotherapy or radiotherapy \</= 4 weeks prior to registration (6 weeks for nitrosureas)
Active bleeding
Known brain mets
Prior thoracic radiotherapy that would lead to overlap with current radiation field.
More than 10% weight loss in 6 months.
Pancoast tumors, supraclavicular or contralateral hilar lymph node involvement
Known HIV positive
Prior treatment with an HDAC inhibitor
Clareo Health | Treatment of Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
